One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Equillium logo
Equillium EQ
$ 1.19 0.38%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Equillium Balance Sheet 2025-2011 | EQ

Brief overview of Equillium's assets and capital

Balance sheet changes are traced across five available annual reports between 2021 and 2025.

Assets fell from $85.4 million to $31.9 million. This may reflect either deliberate optimization or a reduction in business scale.

Growth in the asset base was not matched by liabilities: -62.7% versus -82.6%. The balance sheet moved in a more conservative direction.

Equity funds 89.7% of assets versus 77.9% initially. This creates a conservative balance sheet structure.

The period ended with net cash: net debt stood at -$29.6 million. This supports financial flexibility.

Cash equals 95% of the balance sheet, compared with 59% five periods ago. This is the readily available cushion.

The balance sheet includes a negative accumulated result of -$216.2 million. It should be assessed alongside historical profits and capital distributions.

Overall assessment

Equillium shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.

Annual Balance Sheet Equillium

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-29.6 M -17.7 M -22.4 M -55.5 M -48.8 M -14 M 36.4 M 9.1 M 955 K - - - - - -

Long Term Debt

356 K 187 K 384 K 3.24 M 1.24 M 8.28 M 9.68 M 200 K 8.06 M - - - - - -

Long Term Debt Current

363 K 197 K 440 K 408 K 376 K - - - - - - - - - -

Total Non Current Liabilities

- - - - - 8.33 M 9.81 M 200 K 8.83 M - - - - - -

Total Current Liabilities

2.93 M 6.36 M 27.6 M 32 M 8.92 M 7.24 M 3.88 M 2.03 M - - - - - - -

Total Liabilities

3.29 M 6.54 M 28 M 46.5 M 18.9 M 15.6 M 13.7 M 2.23 M 9.4 M - - - - - -

Deferred Revenue

- - 15.7 M 14.7 M - - - - - - - - - - -

Retained Earnings

-216 M -194 M -186 M -172 M -110 M -70.9 M -41.1 M -15.5 M -2.26 M - - - - - -

Total Assets

31.9 M 25.6 M 50.5 M 78.4 M 85.4 M 85.4 M 55.5 M 67.2 M 7.15 M - - - - - -

Cash and Cash Equivalents

30.3 M 18.1 M 23.2 M 59.1 M 50.4 M 24 M 13.2 M 28.5 M - - - - - - -

Book Value

28.6 M 19.1 M 22.6 M 31.9 M 66.5 M 69.9 M 41.8 M 64.9 M -2.25 M - - - - - -

Total Shareholders Equity

28.6 M 19.1 M 22.6 M 31.9 M 66.5 M 69.9 M 41.8 M 64.9 M -2.25 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Equillium

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

356 K 251 K 187 K 473 K 109 K 149 K 187 K 223 K 259 K 295 K 384 K 498 K 609 K 1.84 M 824 K 4.62 M 5.99 M 7.37 M 1.24 M 8.87 M 10.1 M 7.51 M 8.28 M 9.04 M 9.81 M 9.75 M 9.68 M 9.62 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 163 K 181 K 200 K - - 200 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

3.29 M 3.6 M 6.54 M 3.57 M 7.34 M 6.15 M 6.54 M 11.3 M 20.4 M 22.5 M 28 M 31.1 M 31.8 M 42.5 M 46.5 M 20.5 M 22.2 M 21.6 M 18.9 M 16.7 M 15.1 M 15 M 15.6 M 15.6 M 15.6 M 15.6 M 13.7 M 13.7 M 13.7 M 13.7 M 2.23 M 2.23 M 2.23 M 2.23 M 9.4 M 9.4 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - 2.07 M 8.43 M 13.4 M 15.7 M 15.8 M 14.2 M 14.8 M 14.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-216 M -222 M -194 M -212 M -208 M -202 M -194 M -188 M -188 M -188 M -186 M -183 M -180 M -176 M -172 M -175 M -162 M -147 M -110 M -99.4 M -89.1 M -79.9 M -70.9 M -70.9 M -70.9 M -70.9 M -41.1 M -41.1 M -41.1 M -41.1 M -15.5 M -15.5 M -15.5 M -15.5 M -2.26 M -2.26 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

31.9 M 63.1 M 25.6 M 34.5 M 12.4 M 16.7 M 25.6 M 34.5 M 42.9 M 43.6 M 50.5 M 55.2 M 58.8 M 71.8 M 78.4 M 48.6 M 62.5 M 74.2 M 85.4 M 92.5 M 99.8 M 107 M 85.4 M 85.4 M 85.4 M 85.4 M 55.5 M 55.5 M 55.5 M 55.5 M 67.2 M 67.2 M 67.2 M 67.2 M 7.15 M 7.15 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

30.3 M 61.3 M 18.1 M 33.1 M 11.5 M 14.5 M 18.1 M 15.4 M 11.1 M 11.6 M 23.2 M 34.4 M 25.6 M 24.5 M 59.1 M 25.7 M 23.8 M 26.2 M 50.4 M 77.2 M 73.5 M 50.9 M 24 M 24 M 24 M 24 M 13.2 M 13.2 M 13.2 M 13.2 M 28.5 M 28.5 M 28.5 M 28.5 M 7.1 M 7.1 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

28.6 M 59.5 M 19.1 M 30.9 M 5.06 M 10.6 M 19.1 M 23.2 M 22.4 M 21.1 M 22.6 M 24.1 M 27 M 29.3 M 31.9 M 28.2 M 40.3 M 52.6 M 66.5 M 75.8 M 84.8 M 91.9 M 69.9 M 69.9 M 69.9 M 69.9 M 41.8 M 41.8 M 41.8 M 41.8 M 64.9 M 64.9 M 64.9 M 64.9 M -2.25 M -2.25 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

19.1 M 59.5 M 22.6 M 30.9 M 5.06 M 10.6 M 19.1 M 23.2 M 22.4 M 21.1 M 22.6 M 24.1 M 27 M 29.3 M 31.9 M 28.2 M 40.3 M 52.6 M 66.5 M 75.8 M 84.8 M 91.9 M 69.9 M 69.9 M 69.9 M 69.9 M 41.8 M 41.8 M 41.8 M 41.8 M 64.9 M 64.9 M 64.9 M 64.9 M -2.25 M -2.25 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Equillium, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.12 0.88 % $ 7.05 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.04 1.36 % $ 104 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.8 2.51 % $ 3.52 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 55.9 0.22 % $ 7.48 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.68 1.65 % $ 10.5 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.53 3.93 % $ 1.83 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.63 0.64 % $ 44.3 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 3.53 9.81 % $ 8.23 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.62 3.05 % $ 206 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 21.78 7.39 % $ 1.25 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 24.17 5.8 % $ 1.43 B usaUSA
Xencor Xencor
XNCR
$ 22.85 2.61 % $ 1.7 B usaUSA
Annexon Annexon
ANNX
$ 3.41 1.09 % $ 529 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.76 0.54 % $ 2.9 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.07 0.03 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 13.28 1.16 % $ 16 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.28 5.1 % $ 746 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 499.74 0.08 % $ 128 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.25 0.42 % $ 13.7 B danmarkDanmark
Axon Enterprise Axon Enterprise
AXON
$ 390.29 2.15 % $ 30.5 B usaUSA
AbbVie AbbVie
ABBV
$ 285.42 0.71 % $ 505 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.72 2.35 % $ 97.8 M usaUSA
Altimmune Altimmune
ALT
$ 2.2 2.16 % $ 194 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.22 2.39 % $ 809 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.84 0.87 % $ 1.06 B usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
$ 1.24 5.43 % $ 108 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 12.93 2.64 % $ 779 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.96 4.0 % $ 183 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.28 3.25 % $ 402 M usaUSA